Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation
Journal of Obstetrics and Gynaecology Research, 05/24/2012Kim TE et al.
Cisplatin–based CCRT is well–tolerated. Good clinical response revealed a favorable correlation to survival. A maximal effort to achieve this goal might prolong survival in patients with cervical cancer.
The medical records of 174 patients with International Federation of Gynecology and Obstetrics stage IB1–IVA who were treated at three affiliated hospitals of the Catholic University of Korea between January 1999 and December 2008 were reviewed and analyzed.
Patients received pelvic radiotherapy with one of three regimens of cisplatin–based chemotherapy concurrently and high–dose rate brachytherapy.
The radiation field was extended to include para–aortic lymph nodes, if necessary.
The median follow–up period was 29.5 months (range, 5–96 months).
Using multivariate analysis, stage (P = 0.014), tumor size (P = 0.043), and clinical response (P = 0.001) had a significant effect on overall survival.
Similarly, progression–free survival (PFS) was influenced by stage (P = 0.004), tumor size (P = 0.02), clinical response (P = 0.011), and normalized squamous cell carcinoma antigen level after CCRT (P = 0.007).
The 5–year survival rates were 91.7% (standard error, 5.8%) for stages IB1–IIA, 71.5% (standard error, 7.8%) for stage IIB, 44.9% (standard error, 7.8%) for stage III, and 20.9% (standard error, 12.0%) for stage IVA.
A total of 151 out of 174 patients (86.8%) completed the planned treatment.
Toxicities were manageable with supportive therapy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.